Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.
Androgen receptor
Bladder cancer
Immunohistochemistry
Programmed death ligand 1
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
04
04
2020
accepted:
08
07
2020
pubmed:
18
7
2020
medline:
1
10
2021
entrez:
18
7
2020
Statut:
ppublish
Résumé
The impact of sex hormones on cancer immunotherapy remains controversial. Androgens, via the androgen receptor (AR), may impact the success of immune checkpoint blockade. This study characterizes AR and programmed death ligand-1 (PD-L1) expression in bladder tumors with long clinical follow-up. AR and PD-L1 expression was analyzed using immunohistochemistry on 143 transurethral resection (TUR) and 203 radical cystectomy (RC) specimens. Descriptive statistics and survival analyses assessed the relationship of AR and PD-L1 staining with clinical outcomes of tumor recurrence, progression, and overall survival. AR expression was observed in a higher proportion of TUR than RC specimens (59% vs 35%, p < 0.001). High immune cell (IC) PD-L1 expression was associated with higher stage and grade. Patients with the combination of an absence of AR expression and the highest (> 10%) IC PD-L1 expression in TUR tumors had an increased risk of recurrence and progression. In RC specimens, the expression of AR increased the risk of local recurrence (adjusted hazard ratio (HR) 2.09, 95% CI 0.98-4.45), which was even higher among patients who also had IC PD-L1 expression (HR 4.16, 95% CI 1.28-13.52). For 28 paired metastatic lymph nodes among RC patients, tumor cell PD-L1 expression was significantly correlated (r = 0.48, p = 0.01), while no relationship with IC PD-L1 expression was observed. The expression of AR and its relationship to clinical outcomes appears to vary between non-muscle invasive and muscle-invasive bladder cancer. Our results support the role of IC PD-L1 expression as an independent risk factor for bladder cancer outcomes.
Identifiants
pubmed: 32676741
doi: 10.1007/s00345-020-03358-x
pii: 10.1007/s00345-020-03358-x
doi:
Substances chimiques
AR protein, human
0
B7-H1 Antigen
0
Receptors, Androgen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1549-1558Subventions
Organisme : Fonds de Recherche du Québec - Santé
ID : 32774
Références
Niglio SA et al (2019) programmed death-1 or programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer: a systematic review and meta-analysis. Eur Urol 76:782–789
doi: 10.1016/j.eururo.2019.05.037
Powles T et al (2019) Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 25:1706–1714
doi: 10.1038/s41591-019-0628-7
Necchi A et al (2018) Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol 36:353–3360
Wang S-C et al (2017) The gender difference and mortality-to-incidence ratio relate to health care disparities in bladder cancer: national estimates from 33 countries. Sci Rep 7:4360
doi: 10.1038/s41598-017-04083-z
Conforti F et al (2018) Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol 19:737–746
doi: 10.1016/S1470-2045(18)30261-4
Conforti F et al (2019) Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J Natl Cancer Inst 111:772–781
doi: 10.1093/jnci/djz094
Wallis CJD et al (2019) Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis. JAMA Oncol 5:529–536
doi: 10.1001/jamaoncol.2018.5904
Boorjian SA, Zhu F, Herr HW (2010) The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int 106:357–361
doi: 10.1111/j.1464-410X.2009.09137.x
Palou J et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 62:118–125
doi: 10.1016/j.eururo.2011.10.029
Miyamoto H et al (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99:558–568
doi: 10.1093/jnci/djk113
Kawahara T et al (2016) Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. Urol Oncol 34(432):e15–23
Birtle AJ, Freeman A, Munson P (2004) The androgen receptor revisited in urothelial carcinoma. Histopathology 45:98–99
doi: 10.1111/j.1365-2559.2004.01841.x
Hata S et al (2017) Expression of AR, 5αR1 and 5αR2 in bladder urothelial carcinoma and relationship to clinicopathological factors. Life Sci 190:15–20
doi: 10.1016/j.lfs.2017.09.029
Mir C et al (2011) Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int 108:24–30
doi: 10.1111/j.1464-410X.2010.09834.x
Miyamoto H et al (2012) Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109:1716–1726
doi: 10.1111/j.1464-410X.2011.10706.x
Tyagi A et al (2019) Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder. Urol Oncol 37:492–502
doi: 10.1016/j.urolonc.2019.03.008
Tuygun C et al (2011) Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 29:43–51
doi: 10.1016/j.urolonc.2009.01.033
Necchi A et al (2018) Association of androgen receptor expression on tumor cells and PD-L1 expression in muscle-invasive and metastatic urothelial carcinoma: insights for clinical research. Clin Genitourin Cancer 16:e403–e410
doi: 10.1016/j.clgc.2017.09.016
Boorjian S et al (2004) Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64:383–388
doi: 10.1016/j.urology.2004.03.025
Chen J et al (2017) Expression and clinical significance of androgen receptor in bladder cancer: a meta-analysis. Mol Clin Oncol 7:919–927
doi: 10.3892/mco.2017.1389
Zhu L et al (2019) Prognostic and clinicopathological significance of PD-L1 in patients with bladder cancer: a meta-analysis. Front Pharmacol 10:962
doi: 10.3389/fphar.2019.00962
Ding X et al (2019) Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. Cancer Manag Res 11:4171–4184
doi: 10.2147/CMAR.S176937
Ghate K et al (2019) PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: a meta-analysis. Cancer Treat Rev 76:51–56
doi: 10.1016/j.ctrv.2019.05.002
Reis H et al (2019) PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies. Am J Surg Pathol 43:920–927
doi: 10.1097/PAS.0000000000001264
Rosenberg JE et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. The Lancet 387:1909–1920
doi: 10.1016/S0140-6736(16)00561-4
Burgess EF et al (2019) Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urol Oncol 37(299):e19–299.e25
Izumi K et al (2014) Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 5:12665–12674
doi: 10.18632/oncotarget.2851
McMartin C et al (2019) The use of 5-alpha reductase inhibitors prior to radical cystectomy—Do they render high-grade bladder tumors less aggressive? Clin Genitourin Cancer 17:e1122–e1128
doi: 10.1016/j.clgc.2019.07.016
Shiota M et al (2017) Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5α-reductase inhibitor. J Urol 197:308–313
doi: 10.1016/j.juro.2016.08.006
Mäkelä VJ, Kotsar A, Tammela TLJ, Murtola TJ (2018) Bladder cancer survival of men receiving 5α-reductase inhibitors. J Urol 200:743–748
doi: 10.1016/j.juro.2018.04.082